Creating Lasting Value Investor Presentation - January 2015 BSE:524715 • NSE:SUNPHARMA Bloomberg: SUNP@IN • Reuters: SUN.BO www.sunpharma.com Disclaimer Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as “will”, “aim”, “will likely result”, “would”, “believe”, “may”, “expect”, “will continue”, “anticipate”, “estimate”, “intend”, “plan”, “contemplate”, “seek to”, “future”, “objective”, “goal”, “likely”, “project”, “should”, “potential”, “will pursue” and similar expressions or variations of such expressions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forwardlooking statements. These risks and uncertainties include, but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, obtain regulatory approvals, our provisioning policies, technological changes, investment and business income, cash flow projections, our exposure to market risks as well as other risks. Sun Pharmaceutical Industries Limited does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof. Creating Lasting Value - Investor Presentation 2 Agenda 5 4 3 2 1 Revenue Composition History & Profile Strategy & Approach Growth Key Acquisitions Business Operations Research & Development Management & Governance Financials Geographies API, Finished Dosage & Manufacturing Creating Lasting Value - Investor Presentation 3 Agenda 5 4 3 2 1 Revenue Composition History & Profile Strategy & Approach Growth Key Acquisitions Business Operations Research & Development Management & Governance Financials Geographies API, Finished Dosage & Manufacturing Creating Lasting Value - Investor Presentation 4 Revenue Composition 2013-14 Annual Gross Sales : USD 2,682 million 5 Year CAGR 30% International Generics 5 Year CAGR 38% 60% 12% 5% APIs 5 Year CAGR 11% US Formulations 5 Year CAGR 45% 23% India Branded Generics 5 Year CAGR 14% Finished Dosage sales 95% 5 year CAGR 32% International sales 76% 5 year CAGR 40% 5 Creating Value, Continuously… ‘83 ‘15 2010 2004 1983 Began with 5 products 1997 USD 350mn FCCB raised Acquired Taro 1993 $7.5Mn invested in Caraco 2012 2014 Acquired Dusa Ranbaxy Acquisition (Proposed) 2011 2007 1994 First Research Centre SPARC, Baroda IPO - Rs. 550 Mn raised 2013 Demerger of innovative R&D to SPARC JV for Emerging Markets Acquired URL Pharma JV for Ocular Therapy Sun Pharma Today PART OF 15,000+ Employees Invested $ 820 million in Research 26 Manufacturing facilities in 4 Continents More than 75% of sales from international markets Creating Lasting Value - Investor Presentation 6 Agenda 5 4 3 2 1 Revenue Composition History & Profile Strategy & Approach Growth Key Acquisitions Business Operations Research & Development Management & Governance Financials Geographies API, Finished Dosage & Manufacturing Creating Lasting Value - Investor Presentation 7 Strategy and Approach Create sustainable revenue streams • Focus: Chronic therapies • Differentiation: Technically complex products Seek cost leadership • Vertical integration : Development through Manufacturing (API and Finished Dosage) to Marketing • Optimize operational costs • Speed to market Balance profitability and investments for future • Acquisitions yielding high ROI • Development of complex generics Creating Lasting Value - Investor Presentation 8 Growing Steadily Consistent top-line and bottom-line growth; continuing the trend despite increasing size 2,649 Net Sales (Figures in USD million) EBITDA 1,178 Net Profit 520 396 931 406 68 214 79 98-99 03-04 08-09 13-14 86 17 98-99 03-04 08-09 13-14 14 98-99 03-04 08-09 13-14 9 Sustained Profitability Superior business model Margins consistently higher than peers* Gross Margin EBITDA Margin 90% Net Margin 60% 60% 83% 45% 80% 35% 40% 40% 70% 20% 60% 0% 20% 50% -20% 40% 09-10 10-11 11-12 12-13 13-14 0% 07-08 08-09 09-10 10-11 1108-09 12-13 12 09-1009-10 10-1110-11 11-1211-12 12-13 13-14 Sun Pharma -40% 08-09 09-10 09-10 10-11 10-11 11-12 11-12 12-1312-13 13-14 Range of other Top 10 Pharma Cos. Gross margin= (Net Sales – Material Cost) / Net Sales * 100 •Other top 10 Indian Pharma company include Aurobindo,, Cadila Healthcare, •Cipla, DRL, Glenmark, Ipca, Lupin, Ranbaxy, Torrent and Wockhardt. Average 10 Track record of successful turnaround of 16 acquisitions 8 Early Acquisitions 4 Acquisitions - Bryan Hungary, Able, Chattem 4 Recent Acquisitions Taro, DUSA, URL 3,000 2,500 2,000 1,500 1,000 500 0 Net Sales ($ Mn) EBITDA ($ Mn) Creating Lasting Value - Investor Presentation 11 Key Deals & Rationale Year Deals Country Rationale 2014 In-licensing agreement with Merck for Tildrakizumab a biologic for psoriasis Global Markets Strengthening the specialty product pipeline 2014 Sun Pharma – Ranbaxy Merger (Proposed) US, India, Emerging Markets 5th largest global specialty pharma company, No.1 Pharma company in India & Strong positioning in Emerging Market 2013 Formation of Sun-Intrexon JV Global Markets JV for ocular therapies 2013 Acquired URL’s generic business US Adds 107 products to US portfolio 2012 Acquired DUSA Pharma, Inc. US Access to branded derma product 2011 100% ownership of Caraco US Privatization 2011 Formation of Sun-MSD JV Emerging Markets Develop and commercialize technology based combinations products 2010 Acquired Taro Pharmaceutical Industries Ltd. Israel Dermatology & Topical Product Manufacturing Plant at Israel & Canada 2009 Caraco acquired some products of Forest’s Inwood business US Increased generic product offerings 2008 Acquired Chattem Chemicals, Inc. Tennessee, US Import registration with DEA, API Plant approved by DEA in Tennessee, US 2005 Assets of Able labs New Jersey, US Dosage form plant (NJ, US) and IP 2005 Formulation plant in Bryan Ohio, US Dosage form plant (Ohio, US) 2005 Acquired ICN Hungary Hungary API and dosage form plant (Hungary) 1997 Acquired Caraco Detroit, US Dosage form Plant Creating Lasting Value - Investor Presentation 12 Agenda 5 4 3 2 1 Revenue Composition History & Profile Strategy & Approach Growth Key Acquisitions Business Operations Research & Development Management & Governance Financials Geographies API, Finished Dosage & Manufacturing Creating Lasting Value - Investor Presentation 13 India Branded Generics : Strong Base • Market Share :5.4%* • Leadership in chronic segment; Top 3 in over 50% of more than 500 brands Others 7% Neuro-Psychiatry 27% Opthalmology 5% Antiasthamatic & Antiallergic 4% Musculo-Skeletal & Pain 5% Gynecology & Urology 8% Diabetology 12% Gastroenterology 14% Cardiology 18% * As per AIOCD AWACS –Sept’14 Creating Lasting Value - Investor Presentation 14 Relentless Customer Focus Therapy focused marketing • 4,500+ Field employees (Including Managers) covering 150,000 specialist doctors Strong increase in market share 200 150 100 50 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 Cipla Ranbaxy Sun Cadila Lupin DRL Creating Lasting Value - Investor Presentation Torrent Wockhardt Ipca Year 2000 Market Share indexed to 100 for all companies 15 Therapy Focused Marketing Delivering promotional message to specialty customers. Gastroenterology, Orthopedics Cardiology, Diabetology Psychiatry, Neurology Rheumatology, Dermatology Asthma, COPD Ophthalmology Oncology Urology Creating Lasting Value - Investor Presentation Fertility, Gynecology, Gynecology 16 Preferred Choice of Doctors Leadership in key therapeutic areas* Specialist Top 10 Brands contribute 20% of India Sales June ‘10 June ‘14 Psychiatrists 1 1 Neurologists 1 1 Cardiologists 1 1 Orthopaedic 1 1 Ophthalmologists 1 1 Brand Name Therapy area Gemer Oral antidiabetic Pantocid Proton pump inhibitor/ antiulcerant Susten Women's healthcare Proton pump inhibitor/ antiulcerant Gastroenterologists 2 1 Pantocid-D Nephrologists 4 1 Levipil CNS Diabetologists 2 2 Chest Physicians 4 4 Aztor CVS, cholesterol reducing agent Consulting Physicians 3 5 Oral antidiabetic Dermatologists 14 6 Glucored Group Gynaecologists 4 7 Istamet Antidiabetic Oncologists 5 8 Rozavel CVS Urologists 8 10 Montek-LC Respiratory *Ranks based on prescription share Source-Strategic Marketing Solutions and Research Centre (SMSRC) Pvt. Ltd. Creating Lasting Value - Investor Presentation 17 US Generics Integrated generic manufacturer with flexibility for manufacture onshore / offshore Approvals Therapy wise summary Caraco Pharmaceutical Laboratories Ltd. Skin, 95 CNS, 88 The 100% owned US generics subsidiary, markets own and Sun Pharma ANDAs CVS, 47 Sun Pharmaceutical Pain, 30 Industries, Inc. (SPI) Allergy, 21 A wholly owned subsidiary of Sun Pharma in US Oncology, 20 Metabolism, 12 Taro Pharmaceutical Industries Ltd. Cough / Cold, 6 The 69% owned subsidiary of Sun Pharma URL Pharma. Inc. Urology, 5 Others, 30 A wholly owned subsidiary of Caraco in US As on 30-Sept-2014 Creating Lasting Value - Investor Presentation 18 ANDA Pipeline : Significant ramp up Products Filed and Approved Status 478 449 (including 11 tentative approvals) 397 377 311 225 207 As of Sept’14, ANDAs for 130 products await approval 484 354 344 250 Caraco & URL 18 Products pending (with 4 tentative approvals) 84 Mar-10 Sun Pharma 84 Products pending (with 6 tentative approvals) Taro 28 Products pending (with 1 tentative approvals) Mar-11 Mar-12 Cumulative Products Filed Mar-13 Mar-14 Sep-14 Cumulative Products Approved (Taro numbers added since Mar 2011 & URL numbers added since Mar 2013 ) Creating Lasting Value - Investor Presentation 19 Europe Generic Markets Focused key markets • Working on complex generic products, including injectables • Filings from Indian site An API and Finished Dosage manufacturing site in Hungary with controlled substance capacity Creating Lasting Value - Investor Presentation Focus Countries 20 International Branded Generic Markets Semi Regulated Markets • 48 countries • 866 strong local sales force promotes brands to doctors Replicating the speciality pipeline Product basket width and technology based products as growth drivers CIS Countries China Myanmar Mexico Brazil Map Not to Scale Sri Lanka South Africa Creating Lasting Value - Investor Presentation Focus Markets Other Markets 21 Leveraging through Partnership • Sun Pharma and Merck enter into exclusive worldwide In-licensing agreement for Merck’s investigational therapeutic antibody candidate, called tildrakizumab to strengthen specialty pipeline • Tildrakizumab is an investigational humanized, monoclonal antibody designed to selectively block the cytokine IL-23 • Being Evaluated in Phase 3 registration trials for the treatment of chronic plaque psoriasis, a skin ailment. • Sun Pharma and Merck also have a joint venture for incrementally innovative branded generics targeted at Emerging Markets. • Sun Pharma and Intrexon Form Joint Venture to Develop New Class of Therapeutics for Ocular diseases for global markets • Pipeline of potential Ocular therapies to help millions worldwide suffering from blinding diseases • Equal representation in JV for Sun Pharma and Intrexon. Both partners to share funding and revenues from the joint venture. Creating Lasting Value - Investor Presentation 22 Speciality API High Margin Regulated Markets Strong regulatory capability • Business largely with end users in regulated markets • Over 170 specialty APIs across 8 plants • 264 DMF / CEP filed • 177 approved (including Taro) Creating Lasting Value - Investor Presentation 23 Strong Regulatory Capability International level quality processes and documentation 239 225 206 155 154 264 256 168 174 177 127 89 Mar-10 Mar-11 Mar-12 DMF/CEP Filed Mar-13 Mar-14 Sep-14 DMF/CEP Approved 24 Integrated product dev. and manufacturing network Vertically integrated network across four continents enabling high quality, low cost and a quick market entry across the geographies Ontario (Canada) Aurora Bryan Tennessee Iztapalapa (Mexico) Wilmington M.A. Billerica, M.A Cranbury Philadelphia Tiszavasvari (Hungary) Jammu Sikkim Plant Israel Bangladesh Plant Ahmednagar Maduranthakam Goiânia (Brazil) Halol Karkhadi Ankleshwar Panoli Silvassa Dadra Sun Pharma Taro Pharmaceuticals API and Formulations API Formulations Global networked facilities are FDA, EMEA, TGA approved Creating Lasting Value - Investor Presentation 25 Finished Dosage Manufacturing 18 Manufacturing sites worldwide • India : 6, US : 6 • Canada, Brazil, Mexico, Hungary , Israel, Bangladesh : 1 each • Capacities available for a variety of finished dosage Tablets / Capsules Injectables / Sterile Vials Dry powder Semisolids Ampoules Eye drops Pre-filled Syringes MDI Gels Aerosols Liquids Suppository Lyophilized Units Creating Lasting Value - Investor Presentation 26 API Manufacturing 8 World class locations with all sites ISO 14001, ISO 9002 approved • India : 5, Israel : 1, US : 1, Hungary : 1 Panoli & Ahmednagar (both India) API • International regulatory approvals: USFDA, European Key Plants Over 25 API processes scaled up annually Hungary & Tennessee (US) • Controlled substances manufacture • Stand alone units for peptides, anti-cancer, steroids, sex hormones Creating Lasting Value - Investor Presentation 27 Agenda 5 4 3 2 1 Revenue Composition History & Profile Strategy & Approach Growth Key Acquisitions Business Operations Research & Development Management & Governance Financials Geographies API, Finished Dosage & Manufacturing Creating Lasting Value - Investor Presentation 28 Research and Development • Generic R&D spend around 6-8% of net sales • Strong research teams in generics, finished dosage development, biological support, chemistry Mumbai • 4 R&D centers with about 900 scientists Immediate term ANDA, DMF, Products for India Balancing the risk Medium term Drug delivery systems Baroda Creating Lasting Value - Investor Presentation 29 Agenda 5 4 3 2 1 Revenue Composition History & Profile Strategy & Approach Growth Key Acquisitions Business Operations Research & Development Management & Governance Financials Geographies API, Finished Dosage & Manufacturing Creating Lasting Value - Investor Presentation 30 Corporate Governance Our philosophy on corporate governance envisages working towards high levels of transparency, accountability and consistent value systems across all facets of operations Chairman Sun Pharma Israel Makov Former President & CEO of Teva Pharma. Industries Ltd. Audit Committee Committee chaired by Keki Mistry comprises Hasmukh Shah, Ashwin Dani and S. M. Dadha Independent Directors Keki Mistry Vice Chairman And CEO, HDFC Ashwin Dani Non-Executive Vice Chairman, Asian Paints Ltd. Hasmukh Shah Ex-Chairman Gujarat Gas & Former Chairman And MD, IPCL Rekha Sethi Director General All India Management Association (AIMA) S. Mohanchand Dadha Former Chairman & Managing Director, TDPL Creating Lasting Value - Investor Presentation 31 Shareholding Pattern as on September 30, 2014 • Rs 1,000 Invested in the 1994 IPO is currently worth more than Rs. 700,000 Individuals and Insurance Companies Others 6% 4% Bodies Corporate 3% Financial Inst /Banks 1% Mutual Funds 1% FIIs / Foreign Banks 23% Promoter and promoter group 64% • Total shares outstanding : 2,071 million • Total free float (shares) : 751 million • Average daily trading volume (12 months) : 2.3 million Creating Lasting Value - Investor Presentation 32 Financials Market Capitalisation US$ 27 billion* P&L Summary Net Sales Gross Profit EBITDA Net Profit Net Profit (Adjusted) R&D Spend BS Summary Shareholders Funds Loan Funds Net Fixed Assets Investments Cash and Bank Balances Inventory Sundry Debtors Sundry Creditors Figures in $ million 2009-10 2010-11 2011-12 2012-13 2013-14 847 615 288 285 285 56 1,256 934 428 398 398 73 1,672 1,330 679 555 555 93 2,067 1,685 903 549 656 130 2,649 2,189 1,178 520 937 172 1,734 38 372 701 113 238 260 71 2,124 82 617 499 494 334 247 145 2,392 52 640 433 658 408 406 194 Exchange Rate : * US$1 = Rs 63.33 (As on 31 Dec 2014) # Adjusted for US$ 108 Mn provision related to generic Protonix settlement for the year 2012-13. and Adjusted for US$ 417 Mn provision related to generic Protonix settlement for the year 2013-14 Creating Lasting Value - Investor Presentation # 2,762 37 935 444 748 475 444 195 # 3,143 414 969 464 1,263 520 366 221 33 Financial Ratios 2009-10 Growth (%) Net Sales Gross Profit EBITDA Net Profit Net Profit (Adjusted) Margins (%) Gross Margin EBITDA Margin (%) Net Margin Net Margin (Adjusted) Return (%) Return on Average Capital Employed Return on Average Net Worth Others Debt / Equity Fully Diluted EPS (Rs) Post bonus Fully Diluted EPS (Rs) Post bonus (Adjusted) R&D Spend % of Net Sales Revenue Capital 2010-11 2011-12 (9.2) (17.5) (29.2) (28.0) (28.0) 48.3 52.0 48.7 39.6 39.6 33.2 42.3 58.6 39.3 39.3 23.6 26.7 32.9 (1.1) * 18.2 28.1 29.9 30.5 (5.2) # 42.8 72.6 34.0 33.7 33.7 74.4 34.1 31.7 31.7 79.5 40.6 33.2 33.2 81.5 43.7 26.5 * 31.7 82.6 44.5 19.6 # 35.4 20.5 18.2 23.8 20.7 28.5 24.6 34.7 21.3 38.2 17.6 0.02 0.1 0.1 6.6 6.5 0.4 0.04 0.2 0.2 5.8 5.5 0.4 0.02 0.3 0.3 5.6 4.8 0.4 0.01 0.3 * 0.3 6.3 5.9 0.4 0.13 0.3 # 0.5 6.5 6.2 0.3 * Adjusted for US$ 108 Mn provision related to generic Protonix settlement for the year 2012-13. # Adjusted for US$ 417 Mn provision related to generic Protonix settlement for the year 2013-14 Creating Lasting Value - Investor Presentation 2012-13 2013-14 34 Key Financials Q2 & H1 FY15 Figures in $ million Net Sales Gross Profit Gross Margin EBITDA EBITDA Margin Net Profit Net margin Net Profit (Adjusted) Net margin (Adjusted) R&D R&D as % of Net Sales EPS (Diluted) IN $ EPS (Diluted) IN $ (Adjusted) Q2 FY15 Q2 FY14 CHANGE H1 FY15 H1 FY14 CHANGE 785 678 16% 1442 1301 11% 651 547 19% 1180 1077 10% 83% 81% 82% 83% 357 295 21% 645 570 13% 46% 44% 45% 44% 260 219 19% 492 15 3268% 33% 32% 34% 1% 260 219 19% 492 # 432 14% 33% 32% 34% 33% 52 36 44% 95 73 30% 6.6% 5.3% 6.6% 5.6% 0.13 0.11 19% 0.24 0.01 3268% 0.13 0.11 19% 0.24 0.21 14% FY14 2649 2189 83% 1178 44% 520 20% # 937 35% 172 6.5% 0.25 0.45 # Adjusted for US$ 417 Mn provision related to generic Protonix settlement for the year Q1 FY14 Creating Lasting Value - Investor Presentation 35 Sales Breakup Q2 & H1 FY15 Figures in $ million Q2 FY15 Formulation India US ROW Sub-total Bulk Others Gross Sales 190 481 89 760 35 1 796 Q2 FY14 153 419 79 651 34 (0) 685 CHANGE 24% 15% 12% 17% 2% -373% 16% H1 FY15 H1 FY14 356 870 171 1,397 64 2 1,462 305 783 160 1,248 69 0 1,317 Creating Lasting Value - Investor Presentation CHANGE 17% 11% 7% 12% -7% 582% 11% FY14 611 1,620 316 2,547 133 2 2,682 36 Sun Pharma to acquire Ranbaxy • Sun Pharma to sustain its ranking as the 5th largest global specialty generic pharma company • Pro-forma financials for 12 months ended Dec’ 13 - Sales of US $ 4.2 billion and EBITDA of US $ 1.2 billion. Deal size approximately US$ 4 billion; ~ 2.2x LTM sales • No. 1 pharma company in India • No. 1 by prescriptions in 13 specialty segments, Strong OTC business with trusted brands No. 1 Indian pharma company in US market Over US$ 2 billion in pro-forma sales, Pipeline of 184 ANDAs including high-value FTFs No. 1 in generic dermatology, No. 3 in branded dermatology segments • Approaching US$ 1 bn sales in high-growth emerging markets. Expanding presence in Western Europe • Synergies - Expect US $ 250 mn of revenue & operating synergies by 3rd year post closure of deal • Ranbaxy shareholders to get 0.8 shares of Sun Pharma stock for every share of Ranbaxy- All stock deal • Update – Till date, received approvals from NSE, BSE, shareholders of both companies and competition agencies in applicable markets excluding India and the US. Conditional approval received from Competition Commission of India subject to divestment of 7 brands. Other approvals awaited. • Deal closure – Post receipt of pending regulatory approvals stated above Creating Lasting Value - Investor Presentation 37 Guidance for FY 2014-15 • • • • Overall Consolidated Sales growth : 13-15% over FY14 at constant exchange rate R&D Spend at 6-8% of revenues Target to file 25 ANDAs in US Capex at USD 150 mn • Guidance takes into account: Likely risks associated with the increase in competition for some key products Guidance does not take into account the proposed acquisition of Ranbaxy pending closure of the deal Creating Lasting Value - Investor Presentation 38 For updates and specific queries, please visit www.sunpharma.com or feel free to contact Nimish Desai Tel : +91 22 6645 5645, Ext 5717 Tel Direct : +91 22 66455717 Mobile : +91 98203 30182 [email protected] Frederick Castro Tel : +91 22 6645 5645, Ext 5964 Tel Direct : +91 22 66455964 Mobile : +91 99206 65176 [email protected] © 2014 Sun Pharmaceutical Industries Limited., All Rights Reserved. “SUN Pharma”, The Sun Pharmaceutical Industries Logo are trademarks of Sun Pharmaceutical Industries Limited. In addition to Company data, data from IMS – ORG, CMARC, Stock Exchanges and industry publications has been used for this presentation. This material was used during an oral presentation; it is not a complete record of the discussion. This work may not be used, sold, transferred, adapted, abridged, copied or reproduced in whole on or in part in any manner or form or in any media without the prior written consent. All product names and company names and logos mentioned herein are the trademarks or registered trademarks of their respective owners. Creating Lasting Value - Investor Presentation 39
© Copyright 2024